Whyte Michael P, Griffith Malachi, Trani Lee, Mumm Steven, Gottesman Gary S, McAlister William H, Krysiak Kilannin, Lesurf Robert, Skidmore Zachary L, Campbell Katie M, Rosman Ilana S, Bayliss Susan, Bijanki Vinieth N, Nenninger Angela, Van Tine Brian A, Griffith Obi L, Mardis Elaine R
Center for Metabolic Bone Disease and Molecular Research, Shriners Hospital for Children, St. Louis, MO 63110, USA; Division of Bone and Mineral Diseases, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Genetics, Washington University School of Medicine, St. Louis, MO 63110, USA; Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA.
Bone. 2017 Aug;101:145-155. doi: 10.1016/j.bone.2017.04.010. Epub 2017 Apr 21.
Melorheostosis (MEL) is the rare sporadic dysostosis characterized by monostotic or polyostotic osteosclerosis and hyperostosis often distributed in a sclerotomal pattern. The prevailing hypothesis for MEL invokes postzygotic mosaicism. Sometimes scleroderma-like skin changes, considered a representation of the pathogenetic process of MEL, overlie the bony changes, and sometimes MEL becomes malignant. Osteopoikilosis (OPK) is the autosomal dominant skeletal dysplasia that features symmetrically distributed punctate osteosclerosis due to heterozygous loss-of-function mutation within LEMD3. Rarely, radiographic findings of MEL occur in OPK. However, germline mutation of LEMD3 does not explain sporadic MEL. To explore if mosaicism underlies MEL, we studied a boy with polyostotic MEL and characteristic overlying scleroderma-like skin, a few bony lesions consistent with OPK, and a large epidermal nevus known to usually harbor a HRAS, FGFR3, or PIK3CA gene mutation. Exome sequencing was performed to ~100× average read depth for his two dermatoses, two areas of normal skin, and peripheral blood leukocytes. As expected for non-malignant tissues, the patient's mutation burden in his normal skin and leukocytes was low. He, his mother, and his maternal grandfather carried a heterozygous, germline, in-frame, 24-base-pair deletion in LEMD3. Radiographs of the patient and his mother revealed bony foci consistent with OPK, but she showed no MEL. For the patient, somatic variant analysis, using four algorithms to compare all 20 possible pairwise combinations of his five DNA samples, identified only one high-confidence mutation, heterozygous KRAS Q61H (NM_033360.3:c.183A>C, NP_203524.1:p.Gln61His), in both his dermatoses but absent in his normal skin and blood. Thus, sparing our patient biopsy of his MEL bone, we identified a heterozygous somatic KRAS mutation in his scleroderma-like dermatosis considered a surrogate for MEL. This implicates postzygotic mosaicism of mutated KRAS, perhaps facilitated by germline LEMD3 haploinsufficiency, causing his MEL.
骨纹状肥大(MEL)是一种罕见的散发性骨发育异常,其特征为单骨或多骨的骨硬化和骨质增生,常呈节段性分布。关于MEL的主流假说是合子后镶嵌现象。有时,类似硬皮病的皮肤改变被认为是MEL致病过程的一种表现,覆盖在骨骼改变之上,有时MEL会发生恶变。骨斑点症(OPK)是一种常染色体显性遗传性骨骼发育异常,由于LEMD3基因杂合性功能丧失突变,其特征为对称分布的点状骨硬化。很少有MEL的影像学表现出现在OPK中。然而,LEMD3的种系突变并不能解释散发性MEL。为了探究镶嵌现象是否是MEL的基础,我们研究了一名患有多骨性MEL且有典型的类似硬皮病皮肤覆盖、一些与OPK一致的骨病变以及一个通常携带HRAS、FGFR3或PIK3CA基因突变的大表皮痣的男孩。对他的两种皮肤病、两个正常皮肤区域和外周血白细胞进行外显子测序,平均测序深度约为100倍。正如非恶性组织所预期的那样,患者正常皮肤和白细胞中的突变负荷较低。他、他的母亲和他的外祖父在LEMD3基因中携带一个杂合的、种系的、框内的24个碱基对缺失。患者及其母亲的X线片显示有与OPK一致的骨病灶,但她没有MEL表现。对于该患者,使用四种算法对其五个DNA样本的所有20种可能的两两组合进行比较的体细胞变异分析,仅在他的两种皮肤病中鉴定出一个高置信度突变,即杂合的KRAS Q61H(NM_033360.3:c.183A>C,NP_203524.1:p.Gln61His),而在他的正常皮肤和血液中未出现。因此,在未对患者的MEL骨进行活检的情况下,我们在他被认为是MEL替代物的类似硬皮病的皮肤病中鉴定出一个杂合的体细胞KRAS突变。这意味着突变的KRAS的合子后镶嵌现象,可能是由种系LEMD3单倍体不足促成的,导致了他的MEL。